Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

5847 - Outcome of an active surveillance programme for patients (pts) with uveal melanoma (UM) after primary curative therapy (PTx): single-institution 10-year experience

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Cancer Prevention

Tumour Site

Melanoma

Presenters

Cha Len Lee

Citation

Annals of Oncology (2018) 29 (suppl_8): viii442-viii466. 10.1093/annonc/mdy289

Authors

C.L. Lee1, G. Gullo1, N. Horgan2, D. Smith1, M. Moran1, J.P. Crown1

Author affiliations

  • 1 Medical Oncology, St Vincents University Hospital, 4 - Dublin/IE
  • 2 Surgery, Royal Victoria Eye & Ear Hospital,, Dublin/IE
More

Resources

Abstract 5847

Background

About 30% of pts with UM develop metastatic disease (MUM) despite PTx. MUM has poor prognosis and no systemic treatment (STx) has been proven to improve overall survival (OS). The role of active surveillance after PTx is still controversial.

Methods

We performed an outcome analysis of all UM pts prospectively registered onto our active surveillance programme after PTx. All pts had systemic staging at diagnosis and then 6-monthly liver imaging (CT triple-phase, MRI, ultrasound) and clinical review for the first 5 years and 12-monthly afterwards. Progression-free survival (PFS) was calculated from time of first systemic relapse to first disease progression, OS from time of first systemic relapse to death or latest FU.

Results

Out of 169 pts registered between April 2008 and April 2018, 32 (19%) developed MUM during surveillance: 14 pts (44%) relapsed <2 yrs, 14 (44%) >2 and <5 yrs, 4 (12%) >5 yrs from PTx. Median FU is 46.8 mos. MUM pts characteristics: males 17 (53%); median age 59yrs (range 31-86); median tumour thickness at diagnosis 9mm (range 3-22); sites of metastases: liver only 10 (31%), liver + other sites 19 (60%), extra-hepatic only 3 (9%). Relapses were asymptomatic and detected on surveillance imaging in 25 (78%) pts. Median duration to relapse after PTx is 27.4 mos. Eight pts (25%) were upfront resectable (PRx) and underwent radical hepatic metastasectomies, 24 pts (75%) were non-resectable (NRx) and underwent immunotherapy (n = 12), other systemic therapies (n = 5) [4 chemotherapy, 1 BRAF inhibitor], locoregional Tx (n = 3) [2 Delcath, 1 RFA], best supportive care (n = 4). At median FU of 46.8 mos (0-120 mos), 27 pts have died and the median OS is 13.5mos. PFS was longer in PRx pts compared to NRx pts (PFS: 9.8 vs 4.4 mos / OS: 20.7 vs 39.3 mos). All 8 resectable pts developed further disease relapse [median time to hepatic relapse 9.8 mons (range 5.2 -13.1)].

Conclusions

Our data indicate that active surveillance after PTx of UM can allow detection of asymptomatic potentially resectable liver metastases, especially in pts with high risk UM (i.e. thickness >5mm). Although durable remission after hepatic metastasectomy is rare, PFS and OS may be meaningfully prolonged.

Clinical trial identification

Legal entity responsible for the study

St Vincents' Hospitals, Dublin, Ireland.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.